Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in first-line metastatic nonsquamous NSCLC
MOH_2017-03-09_000217Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atezolizumab, carboplatin, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Started Mar 2016; status: active, not recruiting.
02
Drugs
atezolizumabcarboplatincisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-03-09_000217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-09_000217.